Jivi User Manual

Listing Results Jivi User Manual

Frequently Asked Questions

• What is Jivi and how does it work?

  The active substance in Jivi, damoctocog alfa pegol, works in the same way as the body’s factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of the bleeding disorder.

• What is the age limit for Jivi?

  Learn about possible savings and co-pay support for Jivi®. EHL, extended half-life; rFVIII, recombinant Factor VIII. Jivi is not indicated for use in children less than 12 years of age due to a greater risk for hypersensitivity reactions. Jivi is not indicated for use in previously untreated patients (PUPs).

• What is the shelf life of Jivi?

  Store Jivi at +2°C to +8°C (36°F to 46°F) for up to 24 months from the date of manufacture. Within this period, Jivi may be stored for a period of up to 6 months at temperatures up to +25°C or 77°F. Record the starting date of room temperature storage clearly on the unopened product carton.

• How do you administer Jivi infusion?

  Attach the syringe to the infusion set provided and inject the reconstituted product intravenously (K). The entire dose of Jivi can usually be infused within 1 to 15 minutes. The maximum rate is 2.5 mL per minute. Your healthcare provider will determine the rate of administration that is best for you.

• What is Jivi used to treat?

  Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A. Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A.

• Is Jivi approved in the EU?

  The European Medicines Agency decided that Jivi’s benefits are greater than its risks and it can be authorised for use in the EU. Studies show that Jivi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.

• Is Jivi safe for patients with haemophilia A?

  Studies show that Jivi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.

• Is Jivi safe for children?

  Since this could potentially cause problems especially in children below 12 years of age, Jivi is only approved for use in adults and children from 12 years of age. What measures are being taken to ensure the safe and effective use of Jivi?